Overview
Cardiosclerosis in transplanted hearts refers to the development of fibrotic and sclerotic changes within the myocardium, often complicating post-transplant outcomes and potentially leading to impaired cardiac function 1.Diagnosis
Histological Examination: Cryostat sections using antibodies to identify fibronectin and collagen types I, III, IV, V in extracellular matrix can aid in diagnosing the extent of fibrosis 1.
Plasma Protein Analysis: Monitoring levels of fibrinogen, plasminogen, and other hemostatic components may provide insights into the progression of cardiosclerosis 2.Management
Fibrinolytic Activity Enhancement: Agents that increase fibrinolytic activity, such as those observed with clofibrate treatment, may be beneficial 2.
Lipid Modulation: Clofibrate (1.5 g/day) shows potential in modulating plasma proteins, including decreasing fibrinogen and increasing fibrinolytic activity, though specific application in transplanted hearts requires further study 2.Special Populations
Elderly: The study population included elderly subjects (60-70 years), suggesting that age-related changes in extracellular matrix composition may influence cardiosclerosis progression 1.Key Recommendations
Utilize histological assessment with specific antibodies for extracellular matrix proteins to monitor and diagnose cardiosclerotic changes in transplanted hearts (Evidence: Moderate 1).
Consider monitoring plasma fibrinogen and fibrinolytic activity as biomarkers for assessing disease progression in patients with transplanted hearts (Evidence: Moderate 2).
Evaluate the role of lipid-lowering agents like clofibrate in managing plasma proteins associated with hemostatic mechanisms, though direct evidence in transplanted hearts is limited (Evidence: Weak 2).References
1 Shekhonin BV, Domogatsky SP, Idelson GL, Koteliansky VE. Participance of fibronectin and various collagen types in the formation of fibrous extracellular matrix in cardiosclerosis. Journal of molecular and cellular cardiology 1988. link80077-4)
2 Cederblad G, Korsan-Bengtsen K. Effect of clofibrate on plasma proteins including components of the hemostatic mechanism. Clinica chimica acta; international journal of clinical chemistry 1976. link90366-1)